| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 48.92 | 13.4% | 3.0% |
| Total Income | 55.58 | 21.6% | 5.6% |
| Expenditure | 46.19 | 9.3% | 9.2% |
| PBT | 9.40 | 172.5% | 9.2% |
| Net Profit | 8.04 | 255.4% | 6.6% |
| OPM | 10.30% | 2.73pp | 1.30pp |
| NPM | 14.46% | 9.51pp | 1.90pp |
| EPS | 4.97 | 164.4% | 7.3% |
Kilitch Drugs India Ltd Announces Q2 Results with 40% YoY Revenue Growth
13 Nov 2025 · 13 Nov 2025, 07:04 pm
Summary
Kilitch Drugs India Ltd has announced its Q2 results with a 40% YoY revenue growth. The company's standalone and consolidated financial results for the quarter ended 30 September, 2025 have been approved by the Board of Directors.
Key Highlights
- 1
40% YoY revenue growth in Q2
- 2
Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30 September, 2025 approved by the Board
- 3
Reviewed by C. Sharat & Associates, Chartered Accountants
Management Comments
Mukund Mehta
The above Unaudited Standalone Financial Results of the Company for the quarter and six months ended 30th September, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th November, 2025.
Informational and educational content only. Not investment advice.